A class action lawsuit has been filed against Insulet Corporation for securities fraud related to the safety of its Omnipod insulin delivery products. The suit, pending in the U.S. District Court for the District of Massachusetts, alleges that Insulet misrepresented product safety and its manufacturing quality, concealing defects that risked patient health. On March 12, 2026, the company disclosed a manufacturing issue causing tears in the internal tubing of Omnipod 5 Pods, leading to a 6.88% stock drop from $236.07 to $219.84 per share. A second correction on May 26, 2026, affecting Omnipod 5, Omnipod DASH, and Omnipod Eros systems, triggered a further 5.07% decline from $218.11 to $146.01 per share. Investors have until August 31, 2026 to seek lead plaintiff appointment.
Insulet CorporationSecurities fraud lawsuit alleging misrepresentation of Omnipod safety and manufacturing defects.